AUROPHARMA Intraday Analysis...
75% Offer Save 9000/- Rs (75% off) on Advance 1000 Plan. Pay Just 3000/- One Year of Intraday Subscription Limited Period Offer.

AUROPHARMA Share Price

Open 1361.00 Change Price %
High 1372.00 1 Day 3.65 0.27
Low 1334.00 1 Week 10.25 0.76
Close 1362.55 1 Month 10.45 0.77
Volume 910477 1 Year 742.30 119.68
52 Week High 1432.20
52 Week Low 591.75
AUROPHARMA Important Levels
Resistance 2 1397.78
Resistance 1 1383.26
Pivot 1356.18
Support 1 1341.84
Support 2 1327.32
AUROPHARMA CURRENT MONTH FUTURE
Close 1366.30
Contracts Traded 11253
Open Intrest 9250500
Change In O.I -428000
Lot Size 250
AUROPHARMA CURRENT MONTH OPTION
Most Active Call 1400
Most Active put 1300
Highest O.I Buildup Call 1400
Highest O.I Buildup Put 1300
Expiry Date 28-May-2015
AUROPHARMA ALL MONTHS OPTIONS
For All AUROPHARMA Options Click Here
NSE INDIA Most Active Stocks
NIFTY 8458.95 0.45%
SBIN 282.45 -2.69%
RASOYPR 0.25 0.00%
PUNJLLOYD 26.10 13.73%
UNITECH 14.10 -1.40%
JPASSOCIAT 17.80 -2.47%
CNXIT 11728.40 0.95%
VOLTAS 318.90 10.52%
SUZLON 25.00 -0.99%
IBREALEST 59.45 2.24%
More..
NSE INDIA Top Gainers Stocks
VISESHINFO 0.15 50.00%
VKSPL 0.20 33.33%
MVL 0.30 20.00%
MVL 0.30 20.00%
BLUECHIP 0.30 20.00%
RUPA 271.20 20.00%
SANGAMIND 125.30 19.96%
PANORAMUNI 11.25 19.68%
GTLINFRA 2.45 19.51%
SAMTEL 0.35 16.67%
More..
NSE INDIA Top Losers Stocks
INFINITE 210.00 -20.00%
PARASPETRO 0.20 -20.00%
NEXTMEDIA 9.70 -18.49%
VAIBHAVGBL 660.15 -14.65%
FARMAXIND 0.40 -11.11%
CENTEXT 1.25 -10.71%
RML 318.45 -10.51%
RML 318.45 -10.51%
GANDHITUBE 264.95 -10.43%
TAINWALCHM 21.10 -10.02%
More..

Aurobindo Pharma Limited (NSE: AUROPHARMA)

AUROPHARMA Technical Analysis 5
As on 22nd May 2015 AUROPHARMA Share Price closed @ 1362.55 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 1019.95 & Strong Buy for SHORT-TERM with Stoploss of 1263.78 we also expect STOCK to react on Following IMPORTANT LEVELS.
AUROPHARMA Target for May
1st Target up-side 1424.46
2nd Target up-side 1521.76
3rd Target up-side 1619.05
1st Target down-side 1146.84
2nd Target down-side 1049.54
3rd Target down-side 952.25
AUROPHARMA Synopsis Technicals View
50 Day EMA Close is Above EMA 50 (Short Term)
Bullish
100 Day EMA Close is Above EMA 100 (Mid Term) Bullish
200 Day EMA Close is Above EMA 200 (Long Term) Bullish
MACD (12 26 9) MACD Line is Grater Then SIGNAL Line Bullish
RSI (14) RSI is 68.32 Sideways
MFI (14) MFI is 54.52 Sideways
CCI (20) CCI is -13.16 Sideways
WILLIAM %R (14) William %R is -42.53 Sideways
ADX (14) ADX is Above 20 & +DI is Above -DI Up Trend
PSAR Stoploss For Long Buy 658.30
10 Day Avg Volume Traded 16.95 % More then 10 Day Average Volume
AUROPHARMA Other Details
Segment EQ
Market Capital 25150871552.00
Sector Pharmaceuticals
Industry
Offical website
AUROPHARMA Address
AUROPHARMA
N/A
AUROPHARMA Latest News
Interactive Technical Analysis Chart Aurobindo Pharma Limited ( AUROPHARMA NSE INDIA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Aurobindo Pharma Limited
AUROPHARMA Business Profile
Aurobindo Pharm is in the Pharmaceuticals sector. Founded in 1986 by Mr. P.V. Ramaprasad Reddy, Mr. K. Nityananda Reddy and a small group of highly committed professionals, Aurobindo Pharma was born off a vision. The company commenced operations in 1988-89 with a single unit manufacturing Semi-Synthetic Penicillin (SSP) at Pondicherry. Aurobindo Pharma became a public company in 1992 and listed its shares in the Indian stock exchanges in 1995. In addition to being the market leader in Semi-Synthetic Penicillins, it has a presence in key therapeutic segments such as neurosciences, cardiovascular, anti-retrovirals, anti-diabetics, gastroenterology and cephalosporins, among others. Aurobindo makes use of in-house R&D for rapid filing of patents, Drug Master Files (DMFs), Abbreviated New Drug Applications (ANDAs) and formulation dossiers across the world. Aurobindo Pharma is among the largest filers of DMFs and ANDAs from India. The current market capitalisation stands at Rs 8,284.96 crore.The company has reported a consolidated sales of Rs 1913.86 crore and a Net Profit of Rs 233.86 crore for the quarter ended Sep 2013. The company management includes K Ragunathan - Non Executive Chairman, K Nithyananda Reddy - Vice Chairman & Whole Time Dir, N Govindarajan - Managing Director, M Sivakumaran - Whole Time Director, M Madan Mohan Reddy - Whole Time Director, P V Ramprasad Reddy - Non Executive Director, P Sarath Chandra Reddy - Non Executive Director, M Sitarama Murthy - Non Executive Director, D Rajagopala Reddy - Non Executive Director, C Channa Reddy - Non Executive Director. It is listed on the BSE with a BSE Code of 524804 and the NSE with an NSE Code of AUROPHARMA. Its Registered office is at Plot No. 2, Maitrivihar,,Ameerpet Hyderabad,Andhra Pradesh - 500038.